(Press-News.org) WORCESTER, MA - A novel molecule designed by scientists at the University of Massachusetts Medical School and the University of Virginia inhibits progression of a hard-to-treat form of recurring acute myeloid leukemia (AML) in patient tissue. The small molecule is one of the first designed to specifically target a cancer-causing transcription factor. Previously thought to be an undruggable target, this strategy may be used to design other novel molecules that can specifically inhibit cancer-causing transcription factors. Details of the work were published in Science.
Transcription factors are single- or multi-protein complexes that regulate transcription of DNA into messenger RNA and gene expression by binding to regions on the genome next to a gene. Mutations in transcription factors can result in altered gene expression programs that give way to new, cancer-causing functions. Although these aberrant transcription factors are promising targets for new therapeutics, the complexity of interrupting very specific protein-to-protein interactions has made it difficult to find small molecules or design drugs that treat these cancers.
"When we look at inhibitors, they usually target an enzyme or receptor. There aren't a lot of good examples of transcription factor inhibitors in clinical trials," said Lucio H. Castilla, PhD, associate professor of molecular, cell and cancer biology and co-leader of the study. "Here, we've used our extensive knowledge of a mutant transcription factor found in a subset for acute myeloid leukemia patients to design a molecule that can specifically sequester only the oncogenic mutant. This leaves the normal transcription factor to bind to the DNA and restore gene expression."
Acute myeloid leukemia causes a rapid growth in abnormal white blood cells that accumulate in the bone borrow and interfere with the production of red blood cells. It is the most common form of adult leukemia and survival rates vary depending on specific genetic subsets. Typical treatment involves nonselective chemotherapy, but that can be taxing on some populations, especially the elderly. Therapeutic approaches that target specific genetic anomalies have the potential to be less toxic and yield better results.
AML patients with an inversion on chromosome 16 (known as inv(16) AML) typically respond to initial chemotherapy treatment, but recurrences are likely in a fraction of cases. Leukemia in these patients is caused by a small reversal of the DNA sequence on chromosome 16 that combines a gene which controls production of blood cells and one involved in muscle physiology. When healthy, the core-binding factor-beta (CBFB) protein typically binds with the RUNX protein to form a transcription factor that regulates a number of genes that control production of red and white blood cells. In AML cells with inv(16), the CBFB gene is fused with the smooth muscle myosin heavy chain (SMMHC) gene, and the activity of the CBFB-SMMHC fusion protein causes leukemia.
John H. Bushweller, PhD, a professor of biochemistry at the University of Virginia, screened a library of small molecules and found that the molecule AI-4-57 inhibited the binding of RUNX and CBFB-SMMHC. However, the activity of this molecule was not enough to have a therapeutic effect; by only treating a portion of the AML cells, enough would be left behind for the cancer to return and be resistant to further chemotherapy.
To overcome this problem, Castilla and Bushweller established a collaboration to modify the initial compound to specifically target only the mutant transcription factor (CBFB-SMMHC ) while leaving the normal one (CBFB) being produced by the other copy of chromosome 16 free to do its job of regulating blood cell production.
Taking advantage of the structural differences between the mutant and normal protein, the researchers were able to devise a new compound having the effect they sought. Because normal CBFB is monomeric and CBFB-SMMHC is oligomeric, they developed a bivalent version of the initially screened compound -- AI-4-57. After further refinement, the new drug AI-10-49 prolonged the survival rate of mice with inv(16) AML and was successful in treating in vitro leukemia lines taken from patients.
The polyvalent strategy may serve as a template for new drug discovery efforts focused on selective modulation of aberrant fusion proteins arriving from chromosomal translocation events, wrote Angela N. Koehler, PhD, assistant professor of biological engineering at the Massachusetts Institute of Technology, in a review accompanying the study. This study also serves as a "proof of concept for targeted therapies aimed at dysregulated transcription and should inspire the development of additional directed approaches to control aberrant transcription factor function in cancer and other diseases."
The next step for Castilla's team is to better understand how the newly designed molecule directs the cells expressing CBFB-SMMHC to die while spearing the normal cells of the patient.
INFORMATION:
About the University of Massachusetts Medical School
The University of Massachusetts Medical School (UMMS), one of five campuses of the University system, comprises the School of Medicine, the Graduate School of Biomedical Sciences, the Graduate School of Nursing, a thriving research enterprise and an innovative public service initiative, Commonwealth Medicine. Its mission is to advance the health of the people of the commonwealth through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education. The Medical School attracts more than $240 million annually in research funding, placing it among the top 50 medical schools in the nation. In 2006, UMMS's Craig C. Mello, PhD, Howard Hughes Medical Institute Investigator and the Blais University Chair in Molecular Medicine, was awarded the Nobel Prize in Physiology or Medicine, along with colleague Andrew Z. Fire, PhD, of Stanford University, for their discoveries related to RNA interference (RNAi). The 2013 opening of the Albert Sherman Center ushered in a new era of biomedical research and education on campus. Designed to maximize collaboration across fields, the Sherman Center is home to scientists pursuing novel research in emerging scientific fields with the goal of translating new discoveries into innovative therapies for human diseases.
The tobacco industry and regulatory authorities should support more relevant and less costly in vitro toxicology testing methods over unreliable animal testing, according to a review of research advances published this week in the comment pages of the peer-reviewed scientific journal Alternatives to Laboratory Animals
The article by researchers from People for the Ethical Treatment of Animals (PETA) and the Physicians Committee for Responsible Medicine (PCRM) comes as the Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee prepares to evaluate ...
Philadelphia, PA, April 1, 2015 - The rapid rise in popularity of energy drinks (EDs), particularly among adolescents (aged 10-19 years) and young adults, has serious implications for cardiac health. In an article published in the Canadian Journal of Cardiology, researchers focus on the pharmacology of EDs, adverse reactions to them, and how the marketing of these drinks as a means to relieve fatigue and improve physical and cognitive performance may be ignoring real dangers.
An international research team led by Fabian Sanchis-Gomar, PhD, MD, of the Research Institute ...
While research shows that nearly all coral reef locations in the Caribbean and Gulf of Mexico will experience bleaching by mid-century, a new study showing in detail when and where bleaching will occur shows great variety in the timing and location of these harmful effects.
The new research published today in Global Change Biology by NOAA scientists and colleagues provides the first fine-scale projections of coral bleaching, an important planning tool for managers.
"Our new local-scale projections will help resource managers better understand and plan for the effects ...
A new genomic analysis of tissue from patients with prostate cancer has added more evidence that cells within metastases from such tumors can migrate to other body parts and form new sites of spread on their own.
Results of the analysis undermine anew long-held beliefs that cells with metastatic potential originate solely from the original or primary site of a cancer, according to the scientists who performed the study.
"The idea that metastatic tumors can seed and establish other metastatic tumors in patients is different from traditional theories that the primary ...
As part of an effort to understand how an experimental drug for atherosclerosis causes the build-up of fat in the liver, scientists have developed a computer model that can predict how the rate at which liver stores fat in response to various situations. Being able to model liver fat storage gives researchers a way to predict the side effects of drugs and environmental factors at much earlier stages in the research and drug development process, possibly reducing the number of experiments involving animal models. Additionally, this computer simulation helps describe all ...
While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.
"We hope that our study will contribute to intensified research efforts on the definition of androgen deficiency in women (e.g. which levels of androgens in the blood should be considered too low?), the ...
Jacksonville, Fla. (April 1, 2015) - Training pediatric primary care providers to screen and assess depression and suicide risk in adolescent patients improved providers' confidence and knowledge of these conditions and increased frequency of screenings for this critical patient population. The study, published in the May/June issue of Academic Pediatrics, demonstrates an effective tool for improving recognition of adolescent depression.
"Adolescent depression is woefully underrecognized and undertreated," said Elise Fallucco, MD, a lead author of the study and child ...
The name sounds like something Marvin the Martian might have built, but the "nanomechanical plasmonic phase modulator" is not a doomsday device. Developed by a team of government and university researchers, including physicists from the National Institute of Standards and Technology (NIST), the innovation harnesses tiny electron waves called plasmons. It's a step towards enabling computers to process information hundreds of times faster than today's machines.
Computers currently shuttle information around using electricity traveling down nanoscale metal wires. Although ...
Annapolis, Md -- New research published today in Nature Communications provides insight into how large-scale deforestation could impact global food production by triggering changes in local climate. In the study, researchers from the United States and China zero in on albedo (the amount of the sun's radiation reflected from Earth's surface) and evapotranspiration (the transport of water into the atmosphere from soil, vegetation, and other surfaces) as the primary drivers of changes in local temperature.
The research is the first global analysis of the effects of forest ...
If you want the benefits of medical marijuana without the "unwanted side effects" of cannabis, new research should leave you on a high note. According to a research report appearing in the April 2015 issue of The FASEB Journal, fenofibrate, also known by the brand name Tricor®, may benefit a wide range of health issues, such as pain, appetite stimulation, nausea, as well as immune and various psychiatric and neurological conditions. This suggests that fenofibrate may be the starting point for a new class of cannabis-like drugs to treat these types of conditions.
"By ...
